Novo Nordisk launches first GLP-1 weight loss pill Wegovy in US at lower price than injections
By
andsoitis
Sesame, salt, and substance. A flagship bake.
Summary
Novo Nordisk has launched the first pill version of its blockbuster GLP-1 weight loss drug Wegovy in the US at a significantly lower price than the injectable versions. The once-a-day pill, approved by the FDA just before Christmas, is the first and only oral GLP-1 medication on the market that mimics the hormone to reduce appetite. This launch accelerates a price war in the weight loss drug sector, as Novo Nordisk aims to make the treatment more accessible while competing with other pharmaceutical companies in the rapidly growing GLP-1 market.
Key quotes
· 3 pulledThe first pill version of the blockbuster GLP-1 weight loss drugs has been launched in the US by Novo Nordisk at a lower cost than jab varieties, accelerating a price war in the sector.
The Danish pharmaceutical company said on Monday that its once-a-day Wegovy pill, which received approval from the US regulator just before Christmas, was now available in the country.
It launched the drug – the first and only pill on the market that imitates the GLP-1 hormone to reduce appetite – at significantly lower prices than injectable versions.
You might also wanna read
GLP-1 Prescriptions Rise as U.S. Obesity Rates Show Modest Decline, New Data Indicates
New data from EPIC Research shows that GLP-1 medications like Ozempic and Wegovy are having a population-wide impact on obesity rates. As pr
gizmodo.com·2d ago
CVS Health to reinstate Zepbound coverage, add new weight-loss pill Foundayo to drug plans
CVS Health, through its pharmacy benefit manager CVS Caremark, will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound starti
bit.ly·2d ago
CVS Health to restore Zepbound coverage and add Eli Lilly's new obesity pill to drug plans
CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound starting October 1 and add coverage of Lilly's newly approved
cnb.cx·3d ago
GLP-1 weight loss drugs reduce food spending, creating a $6.5 billion challenge for major grocery retailers
The article discusses how GLP-1 weight loss drugs like tirzepatide are significantly impacting consumer spending on food, creating a $6.5 bi
bit.ly·3d ago